LENZ Therapeutics Inc Dossier - Source-backed chat

LENZ Therapeutics Inc

LENZNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.42

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $3.79Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $119.1M

Enterprise Value $94.9M

Shares Outstanding 32.4M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

LENZ Therapeutics is transitioning from a clinical-stage biotech to a commercial-stage ophthalmology leader following the FDA approval of VIZZ (aceclidine ophthalmic solution 1.44%) in July 2025 and its subsequent launch in October 2025. VIZZ is a highly differentiated, pupil-selective miotic designed to improve near vision in presbyopia patients without compromising distance vision. While early commercial adoption has been slower than initial optimistic targets, leading to a downward revision in near-term consensus estimates, the underlying fundamentals remain strong. VIZZ is demonstrating superior real-world productivity (30% more scripts per prescriber than its predecessor VUITY at the same stage). Backed by a robust cash position of $258.4 million as of March 31, 2026, and a capital-efficient R&D profile, LENZ is well-positioned to fund operations through to positive cash flow. International expansion via high-value licensing partnerships (such as Everest Medicines in Greater China and Lunatus in the Middle East) provides additional non-dilutive funding and commercial upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$24.00

High · most bullish analyst$60.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

New patient adoption remains sluggish due to high out-of-pocket costs or patient reluctance to adopt daily eye drops. High SG&A expenses from DTC marketing and sales force expansion persist, leading to a faster-than-expected cash burn. Refill rates disappoint as patient cohorts mature, raising concerns about long-term product adherence and forcing the company to seek additional dilutive capital.

Base CaseCentral scenario

VIZZ adoption accelerates steadily throughout 2026 and 2027, driven by expanded sales force execution and targeted DTC campaigns. Refill rates stabilize at encouraging levels, confirming a durable patient base. Regulatory approvals in Europe (EMA) and the UK (MHRA) are secured in late 2026 or early 2027, triggering milestone payments from international partners. The company achieves positive operating cash flow within its existing cash runway without requiring dilutive equity financing.

Bull CaseUpside scenario

The bull case for LENZ Therapeutics centers on the rapid commercial scaling of VIZZ (LNZ100) in the US, supported by its highly differentiated pupil-selective mechanism of action that avoids the headaches and myopic shifts associated with older miotics like pilocarpine. This clinical superiority is expected to drive strong real-world prescriber adoption and high patient refill rates. Furthermore, non-dilutive funding and high-margin revenue layers from international partnerships—such as Everest Medicines in Greater China (with up to $85 million in milestones plus royalties) and Lunatus in the Middle East—provide significant global upside and a clear path to profitability within three years, backed by a robust cash runway of over $250 million.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated product profile: VIZZ is the first and only FDA-approved aceclidine-based eye drop, offering rapid onset (30 mins) and long duration (10 hours) without the distance vision impairment common in older miotics.
Strong balance sheet: $258.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, provides a multi-year runway to fund commercialization to positive cash flow.
High operating leverage: R&D expenses have dropped to near-zero post-approval, allowing the company to focus capital on commercial execution and target high gross margins (~90% over time).
Global commercial partnerships: Established licensing deals in Greater China, South Korea, and the Middle East provide non-dilutive milestone payments and future royalty streams.

Key Investment Risks

Commercial execution risk: Slower-than-expected initial patient adoption and the critical need to prove high refill/retention rates as patient cohorts mature.
High near-term cash burn: Elevated SG&A expenses ($45.0 million in Q1 2026) driven by heavy investments in sales force expansion and DTC marketing campaigns.
Market competition: Competition from existing treatments (Vuity, Qlosi) and potential future entries in the presbyopia space.

Thesis Invalidation Triggers

A material decline in quarterly prescription growth or a sharp drop in patient refill rates in H2 2026.
Failure to obtain regulatory approvals from the EMA or MHRA, or significant delays in international partner launches.
Cash burn remaining elevated above revised guidance, accelerating the timeline to a dilutive capital raise.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.